Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 May 2019 | Story Igno van Niekerk | Photo Stephen Collett
Digital storytelling
Collaborating for the common good are from left: Willem Ellis, Karen Venter, Dr Deidre van Rooyen, Prof Hendri Kroukamp, Bishop Billyboy Ramahlele, and Dr Johan van Zyl.

Prof Hendri Kroukamp, Dean of the Faculty of Management Sciences quoted the Cat Stevens song I can’t keep it in, to capture the excitement surrounding the opening of a Digital Storytelling Lab on the Bloemfontein Campus on 10 May 2019.

After months of hard work by Dr Deidre van Rooyen, Willem Ellis, Karen Venter, as well as the staff of the University of the Free State’s (UFS) Centre for Development Support, the Common Good First lab was completed just in time for the launch attended by about 50 delegates from other South African universities, as well as private and public institutions.

Stories meet technology

In a message, from Prof Puleng LenkaBula, Vice-Rector: Institutional Change, Student Affairs, and Community Engagement, informed the audience that the launch heralded the joining of the old world of stories with the new world of digital technology. Julie Adair, Director of Digital Collaboration at Glasgow Caledonian University, Scotland, welcomed the UFS as a partner to this international social innovation collaborative project in a video message. 

Dr Van Rooyen, the project manager for the UFS, explained how she got involved in the Common Good First project, what the benefits of digital storytelling are, as well as what opportunities the lab creates for cooperation between role players involved in social innovation projects. 

Why the Common Good First lab?

The purpose of the lab is to create a digital network to identify, showcase and connect social innovation projects in South Africa to one another and to universities around the world for research, student engagement and learning and teaching. The lab has been fitted with state-of-the-art equipment for recording and digitising the stories that result from social innovation projects.

In a live Skype session with Dr Il-Haam Petersen, Postdoctoral Research Fellow at the Human Sciences Research Council (HSRC), and some of the recent successes of the digital stories in Philippi in the Western Cape were shared.

Bishop Billyboy Ramahlele, UFS Director Community Engagement did the final honours by cutting the ribbon, declaring the lab open, and sharing the dream that the work done in this lab will contribute to positive relationships and cooperation between the university and the community, in making not only the university, but the country and the world a better place.


News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept